Specialized CRO DP Clinical is a privately held CRO with a focus on neurology/CNS, oncology, ophthalmology, infectious disease/vaccines, and rare diseases, offering end-to-end Phase I-IV trial services. Potential sales angle: cross-sell broader trial management, biostatistics, regulatory, safety monitoring, and medical writing to existing and new sponsors in these therapeutic areas.

Mid-sized Advantage With 51-200 employees and revenue in the 10-25 million range, DP Clinical sits between small specialized shops and large CROs, suggesting agility and personalized service. Sales opportunity: position as a high-touch partner for mid-size pharma/biotech companies seeking dedicated program management and rapid turnaround without the overhead of bigger rivals.

Spinal Injury Tie Recent press highlights Isa McClure receiving a FASIA Award and DP Clinical’s involvement in ASIA events, signaling active engagement in spinal injury research. Market opportunity: offer expanded neurology/CNS trial services, patient recruitment collaboration, or safety/pharmacovigilance support for spinal injury and neurodegenerative programs.

Regulatory Excellence Growth milestone includes adding leadership in Regulatory Affairs and Quality Assurance, indicating strengthened compliance capabilities. Sales angle: target sponsors needing robust regulatory submission support, GxP QA, and risk-based monitoring to accelerate approvals and quality assurance across Phase I-IV programs.

Strategic Partnerships Existing collaboration with industry associations and participation in major scientific meetings point to a networked approach and potential for partnerships. Opportunity: propose alliance programs, sponsored research consulting, and co-marketing with other CROs or device/pharma sponsors to expand service scope and geographic reach.